MannKind soars on panel recommendation for inhaled insulin

(Reuters) - MannKind Corp's shares nearly doubled before the bell on Wednesday, after an advisory committee to the U.S. health regulator recommended approval for the drug developer's inhaled insulin treatment. The panel on Tuesday voted 13-1 to recommend approval for patients with type 1 diabetes and unanimously backed it for those with type 2, adding that longer-term studies would still be required to gauge the risk of lung cancer. "Given the number of issues flagged by FDA during the review - especially for the type 1 diabetes indication — there is still a possibility that MannKind may be asked to conduct yet more studies prior to approval to provide better evidence to support the targeted patient population," Guggenheim analysts said in a note.



via Health News Headlines - Yahoo News http://ift.tt/PhDEso